The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...
In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...
A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
The inverted ILM flap technique yields better macular hole closure than ILM peeling for some high myopic macular holes.
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring ...
Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.
Outlook Therapeutics (OTLK) stock rises as the company's wet AMD therapy ONS-5010 undergoes FDA review, with a decision ...
A new technology may allow patients to recover vision for conditions that were previously thought irreversible ...
Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback